This is a type of kidney inflammation that is inherited, meaning it runs in families. It often starts with blood in the urine and can slowly lead to kidney failure over time. There are different types, some involving hearing loss.
Every report comes from a Lived member, sent anonymously.
Have you tried Ramipril for Hereditary Nephritis?
Hereditary nephritis is an inherited kidney disease that causes blood to leak into the urine and, in many people, slowly damages the kidneys over years. Its most common and best-known form is Alport syndrome, and the two names are often used for the same condition. The blood is usually invisible to the eye and found on a urine test, and the amount of blood can increase during a fever or infection. Alport syndrome affects more than the kidneys. Many people, especially boys and men with the X-linked form, develop hearing loss in late childhood or adolescence. Some have changes in the lens or retina of the eye, which a specialist can see but which seldom affect vision. How serious the condition becomes varies widely: some people have blood in the urine for life and nothing more, while others reach kidney failure as young adults.
Alport syndrome is caused by changes (variants) in one of three genes, COL4A3, COL4A4 and COL4A5, that build a type of collagen called collagen IV. This collagen forms part of the kidney's filters, the tiny clusters of blood vessels that clean the blood. When it is faulty, the filter is fragile: blood and protein leak through, and scarring builds up over time. The same collagen is found in the inner ear and the eye, which explains the hearing and eye changes. The way the condition is inherited shapes how severe it tends to be. About two in three cases are X-linked, caused by a variant in COL4A5 on the X chromosome. Males with this form usually develop progressive kidney disease, while females, who have a second working X chromosome, more often have blood in the urine only, although some develop kidney disease later in life. A father cannot pass the X-linked form to his sons. Around 15 percent of cases are autosomal recessive, meaning a person inherited a variant in COL4A3 or COL4A4 from both parents; this form is usually as severe in females as in males. People with a variant in just one copy of COL4A3 or COL4A4 (sometimes called autosomal dominant Alport syndrome or thin basement membrane nephropathy) usually have a much milder course. Severity can differ even within one family, and the specific variant also matters.
The condition is often first suspected when a routine urine test shows blood that does not go away, especially when a relative has had blood in the urine, kidney failure without a clear cause or early hearing loss. A urine test also measures albumin, a protein that should barely appear in urine. The usual measure is the urine albumin-to-creatinine ratio: a result above 30 mg/g on two separate samples, called microalbuminuria, is an early sign that the kidney filters are being damaged, and it is an important point for starting treatment. Blood tests estimate kidney function as the estimated glomerular filtration rate (eGFR), which shows how much filtering capacity remains. Genetic testing of all three collagen IV genes is now the main way to confirm the diagnosis and tells the family which inheritance pattern they are dealing with. Once the X-linked or autosomal recessive form is confirmed genetically, a kidney biopsy is generally not needed. A biopsy may still be useful when the genetic result is unclear, when someone has a single COL4A3 or COL4A4 variant and another kidney disease could also be present, or when kidney function changes faster than expected. Diagnosis usually includes a formal hearing test and an eye examination.
There is currently no cure, but treatment that starts early can delay kidney failure by many years. The main treatment is a blood pressure medicine that blocks the renin-angiotensin system, the hormone pathway that raises pressure inside the kidney's filters. These are angiotensin-converting enzyme (ACE) inhibitors such as ramipril, the most studied in Alport syndrome, or angiotensin receptor blockers (ARBs) such as losartan. They are used for kidney protection even when blood pressure is normal. Current guidelines recommend starting them as soon as microalbuminuria appears in anyone with the condition, and earlier, once blood is found in the urine after age 2, in boys and men with the X-linked form and in anyone with the autosomal recessive form. Registry data suggest early treatment delays kidney failure by a median of about 18 years, though the benefit is smaller with the most severe gene variants or when treatment starts late. Progress is tracked mainly by whether the urine albumin level falls. These medicines can harm a developing baby. Anyone who could become pregnant needs a plan with their kidney doctor before pregnancy, since the medicine is usually stopped as soon as pregnancy is detected. For adults whose albumin stays high despite this treatment, guidelines suggest considering a sodium-glucose cotransporter 2 (SGLT2) inhibitor, a medicine originally developed for diabetes that also protects the kidneys, such as dapagliflozin (Farxiga) or empagliflozin (Jardiance). These have not been studied in children with kidney disease. Other options, including newer drugs and gene therapy, are being studied in clinical trials but are not yet standard care. If the kidneys fail, dialysis or a kidney transplant replaces their work. Alport syndrome does not come back in a transplanted kidney, and transplant outcomes are generally good. Hearing loss is managed with hearing aids, along with support at school or work.
Hereditary nephritis is lifelong, and the outlook depends heavily on the form. Without treatment, most males with the X-linked form reach kidney failure somewhere between their teens and their forties, and people with the autosomal recessive form often reach it in their teens or twenties. About one in five women with the X-linked form reach kidney failure by age 60 without treatment, a risk that falls below one in ten with kidney-protective treatment. Kidney failure is uncommon and usually late in people with a single COL4A3 or COL4A4 variant. In European registry data, the age at which kidney failure occurs has risen by more than five years since about 2005, most likely because more people now start kidney-protective treatment early. Day to day, many people feel well for years. Care centers on regular urine, blood and blood pressure checks, along with periodic hearing tests and eye examinations. Not smoking, staying active and avoiding nonsteroidal anti-inflammatory painkillers such as ibuprofen and naproxen, which can strain the kidneys, help protect kidney function. Hearing loss in childhood needs prompt attention, because untreated hearing loss can delay speech and learning. Because the condition runs in families, a diagnosis often affects parents, siblings and children. Genetic counseling helps relatives decide about testing, and children of an affected parent are usually offered regular urine checks (except sons of a father with the X-linked form, who cannot inherit it). Relatives who carry one variant are generally considered only as a last resort for living kidney donation, since giving a kidney may raise their own risk. Living with a rare, inherited disease can be stressful, and patient organizations and psychological support can help.
Arrange an assessment if a urine test shows blood that persists, if you notice blood in your urine, or if you have a family history of blood in the urine, kidney failure or early hearing loss. Ask for a hearing test if you or your child has trouble following conversations. Contact your kidney care team promptly if you take an ACE inhibitor or ARB and could be pregnant, so the medicine can be reviewed right away. Also ask your team in advance what to do if blood in the urine increases during a fever, or if vomiting or diarrhea makes it hard to keep taking your medicines.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Hereditary Nephritis is like, what's helped you, or ask the community a question.